But_home
But_blogshome
But_forum
Icon_rss_infobarSubscribe to receive updates
on new articles and posts from this blog.
 
Pixel

#37: Reversible anticoagulation in RADAR with Dr Thomas Povsic

Please note that the audio will stop and restart at the beginning of the file when submitting a comment. Veuillez notez que le fichier audio s’arrête et recommence au début lorsqu’un commentaire est publié.
DOWNLOAD
Download this episode in your preferred format:

itunes
mp3

Reversible anticoagulation may open the door to more efficacious treatment and better outcomes in settings such as PCI and valve replacement, as well as bypass surgery. But how does the risk of bleeding fit into the equation? Dr Thomas Povsic joins the show to discuss reversible anticoagulation: the clinical imperative of the RADAR trial, background on aptamer technology, and a discussion of trial results and implications for future research.

Dr Povsic has served as an advisor or consultant for Regado Biosciences and has received grants for clinical research from Regado Biosciences and Baxter International.

For Dr Harrington's disclosures, click here.

See:

RADAR: First significant clinical use of novel reversible anticoagulation system

Comments

Add your own comments



 


This blog on theheart.org is a sounding board for healthcare providers, clinicians, and researchers, and is not intended to supply answers or advice to patients. We reserve the right to remove posts containing inappropriate language, promotional content, personal agendas or hostile intent, and posts from patients asking for medical advice.

In the interest of promoting a balanced exchange, please disclose any relevant relationships or conflicts of interest when posting your comment.

The views and opinions expressed herein are those of the blogger and do not necessarily reflect those of theheart.org.


About The Bob Harrington Show
In his series of discussions, Bob Harrington provides valuable context to news and topics in cardiology by seeking the counsel of thought leaders at the heart of the event. New episodes are published on a monthly basis and are available on both theheart.org and iTunes.
About Robert A Harrington MD
Dr Harrington is the director of the Duke Clinical Research Institute (DCRI) and professor of medicine at Duke University Medical Center, where he practices interventional cardiology.

Dr Harrington's research interests include evaluating antithrombotic therapies to treat acute ischemic heart disease and minimize the acute complications of percutaneous coronary procedures, studying the mechanism of disease of acute coronary syndromes, understanding the issues of risk stratification in the care of patients with acute ischemic coronary syndromes, and trying to better understand and improve upon the methodology of clinical trials.

Author of multiple peer-reviewed manuscripts, reviews, book chapters, and editorials, he was one of the senior coeditors for the 8th edition of the American College of Chest Physicians' Consensus Panel on Antithrombotic and Thrombolytic Drugs. Dr Harrington is an associate editor of the American Heart Journal and an editorial board member for the Journal of the American College of Cardiology. He is a fellow of the ACC, AHA, SCAI, ACCP, and ESC and is a member of the board of trustees of the ACC. He recently served as chair of the FDA Cardiovascular and Renal Drugs Advisory Committee.

When not focusing on acute coronary syndromes, Dr Harrington dreams of being a radio commentator for the Boston Red Sox.